Literature DB >> 30411241

[Adjuvant chemotherapy with cisplatin and gemcitabine after radiochemotherapy with curative intent does not improve relapse-free survival in nasopharyngeal cancer patients with persistently detectable EBV DNA].

Christoph Willich1, Thomas B Brunner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30411241     DOI： 10.1007/s00066-018-1393-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Nasopharyngeal cancer: a promising future.

Authors:  Joseph Wee
Journal:  Lancet Oncol       Date:  2011-12-15       Impact factor: 41.316

2.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

Authors:  M Al-Sarraf; M LeBlanc; P G Giri; K K Fu; J Cooper; T Vuong; A A Forastiere; G Adams; W A Sakr; D E Schuller; J F Ensley
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience.

Authors:  Nancy Lee; Ping Xia; Jeanne M Quivey; Khalil Sultanem; Ian Poon; Clayton Akazawa; Pam Akazawa; Vivian Weinberg; Karen K Fu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

Review 4.  Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.

Authors:  Anne W M Lee; Brigette B Y Ma; Wai Tong Ng; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.

Authors:  Lei Chen; Chao-Su Hu; Xiao-Zhong Chen; Guo-Qing Hu; Zhi-Bin Cheng; Yan Sun; Wei-Xiong Li; Yuan-Yuan Chen; Fang-Yun Xie; Shao-Bo Liang; Yong Chen; Ting-Ting Xu; Bin Li; Guo-Xian Long; Si-Yang Wang; Bao-Min Zheng; Ying Guo; Ying Sun; Yan-Ping Mao; Ling-Long Tang; Yu-Ming Chen; Meng-Zhong Liu; Jun Ma
Journal:  Lancet Oncol       Date:  2011-12-07       Impact factor: 41.316

6.  Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.

Authors:  Lei Chen; Chao-Su Hu; Xiao-Zhong Chen; Guo-Qing Hu; Zhi-Bin Cheng; Yan Sun; Wei-Xiong Li; Yuan-Yuan Chen; Fang-Yun Xie; Shao-Bo Liang; Yong Chen; Ting-Ting Xu; Bin Li; Guo-Xian Long; Si-Yang Wang; Bao-Min Zheng; Ying Guo; Ying Sun; Yan-Ping Mao; Ling-Long Tang; Yu-Ming Chen; Meng-Zhong Liu; Jun Ma
Journal:  Eur J Cancer       Date:  2017-02-22       Impact factor: 9.162

7.  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

Authors:  Li Zhang; Yan Huang; Shaodong Hong; Yunpeng Yang; Gengsheng Yu; Jun Jia; Peijian Peng; Xuan Wu; Qing Lin; Xuping Xi; Jiewen Peng; Mingjun Xu; Dongping Chen; Xiaojun Lu; Rensheng Wang; Xiaolong Cao; Xiaozhong Chen; Zhixiong Lin; Jianping Xiong; Qin Lin; Conghua Xie; Zhihua Li; Jianji Pan; Jingao Li; Shixiu Wu; Yingni Lian; Quanlie Yang; Chong Zhao
Journal:  Lancet       Date:  2016-08-23       Impact factor: 79.321

Review 8.  Nasopharyngeal carcinoma.

Authors:  Melvin L K Chua; Joseph T S Wee; Edwin P Hui; Anthony T C Chan
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.